Patents by Inventor Christina Claus

Christina Claus has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11536716
    Abstract: The present invention relates to a new cell based assay for combined determination of antibody or ligand binding and function in the same vial.
    Type: Grant
    Filed: June 21, 2016
    Date of Patent: December 27, 2022
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Rosmarie Albrecht, Maria Amann, Christina Claus, Sandra Grau-Richards, Joerg Zielonka
  • Patent number: 11447558
    Abstract: The invention relates to new bispecific antigen binding molecules, comprising at least one antigen binding domain capable of specific binding to 4-1BB, at least one moiety capable of specific binding to a target cell antigen, and a Fc domain composed of a first and a second subunit capable of stable association, and to methods of producing these molecules and to methods of using the same.
    Type: Grant
    Filed: June 19, 2019
    Date of Patent: September 20, 2022
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Claudia Ferrara Koller, Christina Claus, Christian Klein, Pablo Umaña, Wei Xu
  • Publication number: 20220267464
    Abstract: The invention relates to new humanized CEA antibodies and to CEA targeting 4-1BBL trimer-containing antigen binding molecules comprising these CEA antibodies as well as their use in the treatment of cancer.
    Type: Application
    Filed: December 17, 2021
    Publication date: August 25, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Claudia Ferrara Koller, Thomas Hofer, Christian Klein, Ekkehard Moessner, Christina Claus, Ralf Hosse, Bianca Scherer, Pablo Umana
  • Publication number: 20220267395
    Abstract: The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one moiety capable of specific binding to a target cell antigen, (b) a polypeptide comprising three ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by peptide linkers and (c) a Fc domain composed of a first and a second subunit capable of stable association, and to methods of producing these molecules and to methods of using the same.
    Type: Application
    Filed: November 18, 2021
    Publication date: August 25, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Maria Amann, Peter Bruenker, Christina Claus, Claudia Ferrara Koller, Sandra Grau-Richards, Christian Klein, Viktor Levitski, Ekkehard Moessner, Pablo Umana
  • Publication number: 20220259327
    Abstract: The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one moiety capable of specific binding to a target cell antigen and (b) a first and a second polypeptide that are linked to each other by a disulfide bond, characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof.
    Type: Application
    Filed: January 21, 2022
    Publication date: August 18, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Maria Amann, Peter Bruenker, Christina Claus, Claudia Ferrara Koller, Sandra Grau-Richards, Christian Klein, Viktor Levitski, Ekkehard Moessner, Joerg Thomas Regula, Pablo Umana
  • Publication number: 20220259326
    Abstract: The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one moiety capable of specific binding to a target cell antigen and (b) a first and a second polypeptide that are linked to each other by a disulfide bond, characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof.
    Type: Application
    Filed: January 21, 2022
    Publication date: August 18, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Maria Amann, Peter Bruenker, Christina Claus, Claudia Ferrara Koller, Sandra Grau-Richards, Christian Klein, Viktor Levitski, Ekkehard Moessner, Joerg Thomas Regula, Pablo Umana
  • Patent number: 11306154
    Abstract: The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one moiety capable of specific binding to a target cell antigen and (b) a first and a second polypeptide that are linked to each other by a disulfide bond, characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof.
    Type: Grant
    Filed: July 25, 2019
    Date of Patent: April 19, 2022
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Maria Amann, Peter Bruenker, Christina Claus, Claudia Ferrara Koller, Sandra Grau-Richards, Christian Klein, Viktor Levitski, Ekkehard Moessner, Joerg Thomas Regula, Pablo Umana
  • Publication number: 20220073646
    Abstract: The invention relates to novel bispecific antigen binding molecules, comprising (a) four moieties capable of specific binding to a costimulatory TNF receptor family member, (b) at least one moiety capable of specific binding to a target cell antigen, and (c) a Fc domain composed of a first and second subunit capable of stable association, and to methods of producing these molecules and to methods of using the same.
    Type: Application
    Filed: June 14, 2021
    Publication date: March 10, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Maria AMANN, Peter BRUENKER, Christina CLAUS, Claudia FERRARA KOLLER, Sandra GRAU-RICHARDS, Ralf HOSSE, Christian KLEIN, Viktor LEVITSKI, Samuel MOSER, Pablo UMANA
  • Patent number: 11267903
    Abstract: The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one moiety capable of specific binding to a target cell antigen and (b) a first and a second polypeptide that are linked to each other by a disulfide bond, characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof.
    Type: Grant
    Filed: July 25, 2019
    Date of Patent: March 8, 2022
    Assignee: Hofmann-La Roche Inc.
    Inventors: Maria Amann, Peter Bruenker, Christina Claus, Claudia Ferrara Koller, Sandra Grau-Richards, Christian Klein, Viktor Levitski, Ekkehard Moessner, Joerg Thomas Regula, Pablo Umana
  • Publication number: 20220025069
    Abstract: The invention relates to bispecific antigen binding molecule capable of bivalent binding to 4-1BB and monovalent binding to a target cell antigen comprising two lipocalin muteins capable of specific binding to 4-1BB and their use in the treatment of cancer or infectious diseases.
    Type: Application
    Filed: October 11, 2021
    Publication date: January 27, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Christina CLAUS, Claudia FERRARA KOLLER, Christian KLEIN, Pablo UMAÑA
  • Patent number: 11149083
    Abstract: The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one antigen binding moiety capable of specific binding to Tenascin-C (TnC) and (b) a first and a second polypeptide that are linked to each other by a disulfide bond, wherein the antigen binding molecules are characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or two fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof. The invention further relates to methods of producing these molecules and to methods of using the same.
    Type: Grant
    Filed: November 9, 2018
    Date of Patent: October 19, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Maria Amann, Peter Bruenker, Christina Claus, Claudia Ferrara Koller, Sandra Grau-Richards, Christian Klein, Viktor Levitski, Ekkehard Moessner, Pablo Umana
  • Publication number: 20210253724
    Abstract: The invention relates to new bispecific antigen binding molecules, comprising (a) a first Fab fragment capable of specific binding to 4-1BB, (b) a second Fab fragment capable of specific binding to a target cell antigen, (c) a third Fab fragment capable of specific binding to 4-1BB, and (d) a Fc domain composed of a first and a second subunit capable of stable association, wherein the Fab fragments (a) and (b) are fused to each other, and to methods of producing these molecules and to methods of using the same.
    Type: Application
    Filed: December 17, 2020
    Publication date: August 19, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Christina CLAUS, Claudia FERRARA KOLLER, Christian KLEIN, Ekkehard MOESSNER, Pablo UMAÑA
  • Publication number: 20210095002
    Abstract: The present invention relates to combination therapies employing 4-1BB (CD137) agonists, in particular 4-1BBL trimer containing antigen binding molecules, in combination with HER-2 targeting agents, the use of these combination therapies for the treatment of cancer, and methods of using the combination therapies.
    Type: Application
    Filed: September 11, 2020
    Publication date: April 1, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Christina CLAUS, Claudia FERRARA KOLLER, Christian KLEIN, Johannes SAM, Pablo UMANA
  • Publication number: 20210024610
    Abstract: The invention relates to Her2 targeting 4-1BB agonists, in particular 4-1BBL trimer-containing antigen binding molecules comprising at least one antigen binding domain capable of specific binding to Her2 and their use in the treatment of cancer as well as their use in combination with T-cell activating anti-CD3 bispecific antibodies.
    Type: Application
    Filed: October 9, 2020
    Publication date: January 28, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Claudia FERRARA KOLLER, Teemu Tapani JUNTTILA, Christian KLEIN, Pablo UMANA, Christina CLAUS
  • Publication number: 20210009656
    Abstract: The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) one Fab domain capable of specific binding to a target cell antigen, (b) a Fc domain composed of a first and a second subunit capable of stable association, and (c) a first polypeptide comprising two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by a peptide linker and a second polypeptide comprising one ectodomain of said TNF ligand family member or a fragment thereof, wherein the first polypeptide is fused at its N-terminus to the C-terminus of one of the subunits of the Fc domain and wherein the second polypeptide is fused at its N-terminus to the C-terminus of the other subunit of the Fc domain, wherein the TNF family ligand trimer-containing antigen binding molecule is monovalent for the binding to the target cell antigen.
    Type: Application
    Filed: September 23, 2020
    Publication date: January 14, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Peter BRUENKER, Claudia Ferrara KOLLER, Sandra GRAU-RICHARDS, Christian KLEIN, Ekkehard MOESSNER, Pablo UMANA, Maria AMANN, Christina CLAUS, Wei XU
  • Publication number: 20200347115
    Abstract: The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising two different fusion polypeptides that comprise a spacer domain, an antigen binding domain and three ectodomains of a TNF ligand member or fragments thereof, wherein two of said ectodomains are separated from each other by a spacer domain comprising at least 25 amino acids and wherein the two fusion polypeptides are covalently associated to each other in the spacer domain
    Type: Application
    Filed: April 29, 2020
    Publication date: November 5, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Harald Duerr, Claudia Ferrara Koller, Guy Georges, Friederike Hesse, Sabine Imhof-Jung, Christina Claus, Wei Xu
  • Publication number: 20200325225
    Abstract: The present invention relates to combination therapies employing tumor targeted anti-CD3 bispecific antibodies and/or agents blocking PD-L1/PD-1 interaction in combination with 4-1BB (CD137) agonists, in particular 4-1BBL trimer containing antigen binding molecules, the use of these combination therapies for the treatment of cancer and methods of using the combination therapies.
    Type: Application
    Filed: March 20, 2020
    Publication date: October 15, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marina BACAC, Christina CLAUS, Claudia FERRARA KOLLER, Christian KLEIN, Sabine LANG, Viktor LEVITSKI, Pablo UMAÑA
  • Publication number: 20200270321
    Abstract: The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one moiety capable of specific binding to a target cell antigen, (b) a polypeptide comprising three ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by peptide linkers and (c) a Fc domain composed of a first and a second subunit capable of stable association, and to methods of producing these molecules and to methods of using the same.
    Type: Application
    Filed: October 15, 2019
    Publication date: August 27, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Maria Amann, Peter Bruenker, Christina Claus, Claudia Ferrara Koller, Sandra Grau-Richards, Christian Klein, Viktor Levitski, Ekkehard Moessner, Pablo Umana
  • Publication number: 20200247904
    Abstract: The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one moiety capable of specific binding to a target cell antigen and (b) a first and a second polypeptide that are linked to each other by a disulfide bond, characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof.
    Type: Application
    Filed: July 25, 2019
    Publication date: August 6, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Maria Amann, Peter Bruenker, Christina Claus, Claudia Ferrara Koller, Sandra Grau-Richards, Christian Klein, Viktor Levitski, Ekkehard Moessner, Joerg Thomas Regula, Pablo Umana
  • Publication number: 20200190206
    Abstract: The invention relates to new bispecific antigen binding molecules, comprising at least one antigen binding domain capable of specific binding to 4-1BB, at least one moiety capable of specific binding to a target cell antigen, and a Fc domain composed of a first and a second subunit capable of stable association, and to methods of producing these molecules and to methods of using the same.
    Type: Application
    Filed: June 19, 2019
    Publication date: June 18, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Claudia FERRARA KOLLER, Christina CLAUS, Christian KLEIN, Pablo UMAÑA, Wei XU